Insider Shareholders with Direct Ownership of Cue Biopharma, Inc. (CUE)
This section provides a comprehensive overview of the insiders with direct ownership of Cue Biopharma, Inc. (CUE). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Cue Biopharma, Inc. Insider List
Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
---|---|---|---|---|---|
Cameron Gray
Director |
71,111 | 51,562 | 687,049 $721,401 | 4 |
Jun 14, 2022
Reduced 6.98%
|
Aaron G.L. Fletcher
Director |
6,548 | 0 | 165,000 $173,250 | 1 |
Nov 24, 2020
Added 3.82%
|
Daniel R Passeri
CHIEF EXECUTIVE OFFICER |
186,400 | 73,799 | 164,578 $172,806 | 7 |
Dec 16, 2024
Added 15.42%
|
Anish Suri
PRESIDENT AND CSO |
135,335 | 79,002 | 135,638 $142,419 | 13 |
Aug 25, 2023
Added 2.86%
|
28,000 | 0 | 28,000 $29,400 | 1 |
May 27, 2022
Added 50.0%
|
|
Kerri Ann Millar
CHIEF FINANCIAL OFFICER |
14,585 | 6,040 | 14,311 $15,026 | 6 |
Aug 22, 2022
Reduced 16.5%
|
Kenneth Pienta
Chief Medical Officer |
36,433 | 33,713 | 2,000 $2,100 | 9 |
Mar 16, 2021
Reduced 18.0%
|
29,858 | 29,501 | 357 $374 | 6 |
Mar 23, 2023
Reduced 96.31%
|